IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

Jorge J. Castillo; Constantine S. Tam; Ramón García‐Sánz; Stephen Opat; Shirley D’Sa; Wojciech Jurczak; Hui‐Peng Lee; Gavin Cull; Roger G. Owen; Paula Marlton; Björn E. Wahlin; Alessandra Tedeschi; Tanya Siddiqi; Christian Buske; Véronique Leblond; Wai‐Yee Chan; Jingjing Schneider; Aileen Cohen; Meletios A Dimopoulos

doi:10.1016/s2152-2650(22)01551-8

Related publications

Article2022

Poster: IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

Jorge J. Castillo, Constantine S. Tam, Ramón García‐Sánz, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Alessandra Tedeschi, Tanya Siddiqi, Christian Buske, Véronique Leblond, Wai‐Yee Chan, Jingjing Schneider, Aileen Cohen, Meletios A Dimopoulos

Article2022

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

Meletios A Dimopoulos, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, H.-P. Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García‐Sánz, H. McCarthy, Stephen P. Mulligan, Andrea Tedeschi, Jorge J. Castillo, Jarosław Czyż, Carlos Fernández de Larrea Rodríguez, David Belada, Edward N. Libby, J. Matous, Mario Motta, Tanya Siddiqi, ,

Article2022

ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).

Constantine S. Tam, Ramón García‐Sánz, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Alessandra Tedeschi, Jorge J. Castillo, Tanya Siddiqi, Christian Buske, Véronique Leblond, Wai‐Yee Chan, Jingjing Schneider, Aileen Cohen, Jane Huang, Meletios A Dimopoulos

Article2020

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Constantine S. Tam, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui-Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Ramón García‐Sánz, Helen O. McCarthy, Stephen P. Mulligan, Alessandra Tedeschi, Jorge J. Castillo, Jarosław Czyż, Carlos Fernández de Larrea, David Belada, Edward N. Libby, Jeffrey Matous, Marina Motta, Tanya Siddiqi, Monica Tani, Marek Trněný, Monique C. Minnema,

Article2020

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).

Constantine S. Tam, Stephen Opat, Shirley D’Sa, Wojciech Jurczak, Hui‐Peng Lee, Gavin Cull, Roger G. Owen, Paula Marlton, Björn E. Wahlin, Alessandra Tedeschi, Jorge J. Castillo, Tanya Siddiqi, Christian Buske, Véronique Leblond, Wai‐Yee Chan, Jingjing Schneider, Sunhee Ro, Aileen Cohen, Jane Huang, Meletios A Dimopoulos

IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

Discussion(0)

Related publications

Poster: IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).